EGI
MRSN

EAM Global Investors’s Mersana Therapeutics MRSN Stock Holding History

EAM Global Investors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,818
Closed -$2.82M – 167
2020
Q2 		$2.82M Buy
+4,818
New +$1.65M 1.27% 15

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

EAM Global Investors's MRSN Position: Q3 2020 in Review

EAM Global Investors sold out of Mersana Therapeutics (MRSN) in Q3 2020, closing a stake of 4,818 shares — an estimated $2.82M sold.

EAM Global Investors first reported a position in MRSN in Q2 2020 and held it in 1 quarter. The position peaked at $2.82M in Q2 2020. 135 funds tracked by Wall St. Rank hold MRSN as of Q3 2020.

  • EAM Global Investors reported no remaining Mersana Therapeutics position as of Q3 2020 after selling out during the quarter.
  • EAM Global Investors sold 4,818 Mersana Therapeutics shares in Q3 2020, an estimated $2.82M.
  • EAM Global Investors first reported a position in Mersana Therapeutics in Q2 2020 and held it in 1 quarter.
  • EAM Global Investors's Mersana Therapeutics position peaked at $2.82M in Q2 2020.
  • 135 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2020.

Based on EAM Global Investors's 13F filing for Q3 2020, filed 13 Nov 2020.